Deal of the Day — limited-time pharmacy picks!
Rybelsus 3mg Tablet

Rybelsus 3mg Tablet

Prescription requiredRx Required

Salt Composition: Semaglutide

Expiry Date: 01/2028

Special offer

Price on Request

Price on Request

Inclusive of all taxes

▼

10 Tablet in Strip

About The Product

Diabetes

Description

Rybelsus 3mg tablet is an oral anti diabetic medicine. It is used to treat type 2 diabetes mellitus in adults.

Its active ingredient is semaglutide which belongs to the drug class of GLP-1 receptor agonist. It helps control the control blood sugar by increasing insulin secretion, slowing gastric emptying and glucose decreasing glucose production by the liver.

The medicine's secondary benefit is, it helps to manage body weight in diabetic patients. Dont take more than the recommended dosage.​​​

Uses

  • Helps manage diabetes

Side Effects

  • Rybelsus tablet cause several side effects but they are manageable with certain medications.
  • Consult a healthcare professional if any of the symptoms persist or worsen: • Nausea • Vomiting • Abdominal pain • Constipation • Diarrhea • Decreased appetite • Allergic reaction (swelling, rash and difficulty in breathing)

How To Use

  • Rybelsus 3mg tablet is taken orally. Do not crush, chew or break the medication just swallow it with whole glass of water.
  • Take the medicine on an empty stomach but try to take it at the same time everyday to enhance the effectiveness of the medication.
  • Never double up the dose on the missed one without consultation with a specialist.
    ​

How It Works

  • Rybeslsus 3mg tablet works by helping increasing insulin level in the body by reducing glucagon production. The medicine belongs to the class of GLP-1 (glucagon like peptide) receptor agonists. It binds and activates to GLP-1 receptor.
  • It acts like a natural hormone in the body that helps to keep the body blood sugar level balance. Also Insulin directs the muscle and fat cells to take in glucose where it is utilized for energy.

Safety Advice

Alcohol
Taking Rybeslsus 3mg tablet with alcohol is may be dangerous to the patient health but consult the doctor before taking the medication.
Pregnancy
Rybeslsus 3mg tablet is not recommended to pregnant and breastfeeding women as it may affect the fetus or newborn. Take guidance from a healthcare expert to ensure safety and precautions.
Breast Feeding
Breastfeeding women should not be advisable for taking Rybeslsus 3mg as the medicine is passed through breast that somehow affect breast milk. Discuss with the doctor for more query.
Driving
Rybeslsus 3mg tablet may not cause dizziness or sleepiness but patient may still experience some side effects. It is important to monitor the response of medication and report any unusual symptoms to the doctor.
Kidney
Kidney patients should take precautions while using Rybeslsus 3mg tablet as dose adjustment and doctor's prescription is much needed.
Liver
Rybeslsus 3mg tablet may interrupt with liver function. Patients with liver disease should consult the doctor before using it.

FAQs

Rybeslsus tablet is an oral anti diabetic medicine that helps improve blood sugar level in patient by producing insulin to the body.

References

• Smits, M. M., & Van Raalte, D.

H. (2021).

Safety of semaglutide. Frontiers in endocrinology, 12, 645563. https://pubmed.ncbi.nlm.nih.gov/34305810/ • Christou, G.

A., Katsiki, N., Blundell, J., Fruhbeck, G., & Kiortsis, D. N.

(2019). Semaglutide as a promising antiobesity drug.

Obesity Reviews, 20(6), 805-815. https://pubmed.ncbi.nlm.nih.gov/30768766/ • Chao, A. M., Tronieri, J.

S., Amaro, A., & Wadden, T. A.

(2023). Semaglutide for the treatment of obesity.

Trends in cardiovascular medicine, 33(3), 159-166. https://pubmed.ncbi.nlm.nih.gov/34942372/ • Bergmann, N. C., Davies, M.

J., Lingvay, I., & Knop, F. K.

(2023). Semaglutide for the treatment of overweight and obesity: a review.

Diabetes, Obesity and Metabolism, 25(1), 18-35. https://pubmed.ncbi.nlm.nih.gov/36254579/ • Marso, S. P., Bain, S.

C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L.

A., ... & Vilsbøll, T. (2016).

Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 375(19), 1834-1844. https://pubmed.ncbi.nlm.nih.gov/27633186/​​

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026